NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Geron Corporation (NASDAQ: GERN) resulting from allegations that Geron may have issued materially misleading business information to the investing public.
On March 27, 2017, STAT published a report by Adam Feuerstein stating that Geron’s recent stock gains were due to “flimsy” claims regarding the efficacy of imetelstat, Geron’s experimental treatment for myelofibrosis. The report states that available data for imetelstat undercuts Geron’s representations as to the drug’s efficacy. On this news, shares of Geron fell $0.83 or over 13% to close at $5.15 per share on March 27, 2018. Geron shares continue to fall sharply during intraday trading on March 28, 2018.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Geron investors. If you purchased shares of Geron please visit the firm’s website at http://www.rosenlegal.com/cases-1310.html to join the class action. You may also contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at firstname.lastname@example.org or email@example.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.